Month: August 2025

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) — As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times Square, NYC on the day with several high-visibility billboards that expose fentanyl risks and urge a nationwide call to action to reduce the stigma around opioid poisonings ensuring that more people can be prepared to save a life. Synthetic opioids, such as fentanyl, are a key driver of the opioid epidemic, contributing to nearly 70 percent of all overdose deaths.2 Its undetectable...

Smarter, faster operations: OMNIQ’s AI-powered machine vision automates license plate scanning and matching, helping staff work more efficiently. Seamless traveler convenience: Pay online or via mobile before, during, or after trips. Reducing missed payments. Hands-on customer service: CMX staff assist travelers, set up permits, process in-person payments, and address any system questions. Reliable revenue for essential services: Efficient follow-up on unpaid citations supports funding for critical needs, like snow removal and ongoing airport operations.SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) —  Houghton County Airport (CMX) is the latest airport to adopt OMNIQ airport management platform, combining advanced AI-powered machine vision with the expertise and dedication of airport staff. Since going live in October 2024,...

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development. “Receiving Orphan Drug Designation from the FDA underscores the significant unmet need faced by people living with CAH,” said Dana Pizzuti, M.D., Chief Medical and Development Officer of Crinetics. “Through atumelnant’s innovative mechanism of action, we have developed an ambitious and uncompromising endpoint for our Phase 3 trial, which can demonstrate the ability...

MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). Advancing a broader fluid management platform: This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and practical implementation support—so hospitals and clinics can standardize how they identify patients, begin ultrafiltration therapy earlier, and sustain programs from the ICU to step-down and hospital-based outpatient settings. The company’s strategy centers on three growth drivers: critical care, cardiac surgery recovery, and hospital-based...

Q2 2025 Results and Strategy Update – Invitation to Extended Presentation 28 August BW Offshore will release its Q2 2025 results on Thursday 28 August at 07:30 CEST. The Company invites to an extended Q2 2025 results presentation including a strategy update, at 09:00 CEST on the same day at Hotel Continental in Oslo, Norway. The presentation will be held by CEO Marco Beenen, CFO Ståle Andreassen and CSO Anders S. Platou. Conference call information: You can follow the presentation via webcast with supporting slides and a Q&A module, available on:   BW Offshore Limited – Q2 Presentation Webcast Please note that if you follow the webcast via the above URL, you may experience a 30 second delay compared to the main conference call. The web page works best in an updated browser – Chrome is recommended. For further information, please...